Although EGFR-TKI treatment shows a durable response against NSCLC harboring EGFR mutations, most patients experience cancer relapse within 1–1.5 years following treatment with first-line 1st- and 2nd-generation (G) EGFR-TKIs. The gene discussed is EGFR; the disease is cancer.